StockMacro
Menu

Freenome

$9.36 -28% in 6 monthsMarket cap $1.0B

FRNM on XNAS, Health Care, Freenome, Inc., job postings

Measures activity, not value. Not investment advice.

Shares fell 33% in one month as the 12-month net loss reached $73.2M with $430M cash.

  • WatchNews flow 11.0 times its usual week, with 11 articles in 7 days

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Freenome Inc is a development-stage, early cancer detection company developing blood-based screening tests leveraging a proprietary artificial intelligence/machine learning multiomics technology platform to transform multi-cancer and ultimately multi-disease detection. It is developing a range of blood-based cancer screening tests.

Industry
Services-medical laboratories (Health Care)
Website
freenome.com
Listed
Nasdaq, US
Last results
10 Nov 2026
Next results
no estimate
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $183.5M, net income $60.1M.
Quarter to 30 Jun 2024: revenue –, net income $87KQuarter to 30 Sep 2024: revenue –, net income $981KQuarter to 31 Dec 2024: revenue –, net income $841KQuarter to 31 Mar 2025: revenue –, net income $679KQuarter to 30 Jun 2025: revenue –, net income $755KQuarter to 30 Sep 2025: revenue $1.0M, net income $145KQuarter to 30 Sep 2025: revenue $1.0M, net income $145KQuarter to 31 Dec 2025: revenue –, net income -$741KQuarter to 31 Mar 2026: revenue –, net income -$52KQuarter to 30 Jun 2026: revenue –, net income -$115KQuarter to 30 Sep 2026: revenue $183.5M, net income $60.1MQuarter to 30 Sep 2026: revenue $183.5M, net income $60.1M
30 Jun 2024RevenueNet incomeNet losstallest bar $183.5M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$183.5M$60.1M
30 Jun 2026–-$115K
31 Mar 2026–-$52K
31 Dec 2025–-$741K
30 Sep 2025$1.0M$145K
30 Jun 2025–$755K
31 Mar 2025–$679K
31 Dec 2024–$841K
30 Sep 2024–$981K
30 Jun 2024–$87K
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +17%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$73.2M -$180.2M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). – –
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 33.5%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -8.2%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -5.9%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -23.7% -10.1%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $430.0M $74.0M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. – –
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). – –
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.16
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $4.32
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 29.1
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 3.6
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 2.6
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 2.2 2.8

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
FreenomeFRNM (this company) $1.0Bloss–––
Castle BiosciencesCSTL $1.0Bloss2.7+9.8%-6.1%
Lumexa ImagingLMRI $1.4B––––
PersonalisPSNL $1.5Bloss19.2+17%-148%
Fulgent GeneticsFLGT $673.9Mloss2.0+4.7%-27.5%
FortreaFTRE $1.8Bloss0.67-3.4%-2.6%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

–

No data for this company

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

–

No data for this company

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

71%

79.6M shares held by 13F filers (30 Sep 2026) of 111.5M outstanding (9 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

4.2%

4.6M shares sold short (30 Oct 2026) of 111.5M outstanding (9 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

8.1

4.6M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+3.4%

4.5M shares sold short in the report before, 4.6M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

42%

42% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 47%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

26

Tracked since 20 Nov 2026

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

Tracking started 20 Nov 2026; the change shows after 30 days.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

–

No data for this company

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$50K

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

12

12 articles in the last 7 days; its usual week has 1.5 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

8.0×

12 articles in the last 7 days; its usual week has 1.5.

Unusual now sharp changes in the last 90 days, compared with its own past

  • First lobbying new, first

Price $9.36 on 20 Nov 2026, -28% over 12 months (12-month range $9.36 to $17.11)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 2 published in the last 12 months (none in the 12 months before).
Revenue per quarter. Revenue $183.5M in the latest quarter, +17628% on a year earlier.
Institutional holders (13F filers). 71 13F filers reported holding it in the latest 13F quarter, 0% on a year earlier.
Lobbying spend. Lobbying spend: $50K published in the last 12 months (none in the 12 months before).

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: insider net buying (open market), capital spending per quarter, federal obligations, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
25 Oct 2026Lobbying filingnew lobbying registration (TODD STRATEGY GROUP)
25 Oct 2026Sharp changeFirst lobbying registration: first lobbying registration: FREENOME: new lobbying registration (TODD STRATEGY GROUP)
18 Aug 20268-K and other filingsRegistered new securities for sale (S-1)
24 Jul 20268-K and other filingsDirector or officer change
24 Jul 20268-K and other filingsChanged its auditor
24 Jul 20268-K and other filingsCompleted an acquisition or asset sale
24 Jul 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
7 Jun 20248-K and other filingsRegistered new securities for sale (S-1)
21 May 20248-K and other filingsRegistered new securities for sale (S-1)
H-1B/E-3 applications certified
Quarter from 1 Oct 2026: 2 published
Revenue per quarter
Quarter ended 30 Sep 2025: $1.0M; public on 13 Nov 2026
Quarter ended 30 Sep 2026: $183.5M, +17628% on a year earlier; public on 13 Nov 2026
Institutional holders (13F filers)
30 Sep 2026 report: 71; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Oct 2026: $50K published

What is unusual now

  • Made public in the last 90 days: it registered for federal lobbying for the first time in our data (Todd Strategy Group).
  • First lobbying registration: registered for federal lobbying for the first time in our data (Todd Strategy Group) Public on 25 Oct 2026.
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 2 published in the last 12 months (none in the 12 months before).
  • Revenue per quarter: Revenue $183.5M in the latest quarter, +17628% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

71 institutions reported shares at the end of Q3 2026, 71% of the shares outstanding; 70 opened a position, 1 sold out. From 13F reports.

Company events

All 9 company events

In 12 months: 2 major agreements, 1 completed deal, 1 auditor change, 1 director or officer change. Results releases and routine reports are left out.

FiledWhat happenedSource
18 Aug 2026Registered new securities for sale (S-1)S-1
23 Jul 2026Director or officer change; Signed a major agreement; Completed an acquisition or asset sale; Changed its auditorSame filing: sold shares privately, changed shareholder rights, change of control, changed its bylaws or fiscal year8-K
5 Dec 2025Signed a major agreementSame filing: sold shares privately8-K
13 Jun 2024Signed a major agreementSame filing: sold shares privately, changed its bylaws or fiscal year8-K
7 Jun 2024Registered new securities for sale (S-1)S-1/A
21 May 2024Registered new securities for sale (S-1)S-1

26 open postings; careers site tracked since 20 Nov 2026. Most in Research & science 19%, Sales & business development 15%, Software engineering 12%, Test, quality & reliability 12%.

PostedJobLocation
20 Nov 2026Senior Research AssociateResearch & scienceBrisbane, California
5 Nov 2026Computational BiologistLegal, policy & complianceRemote
3 Nov 2026Senior Staff Software EngineerSoftware engineeringRemote
2 Nov 2026Senior Manager, Total RewardsPeople & recruitingBrisbane, California
29 Oct 2026Senior Systems Integration EngineerProgram & project managementBrisbane, California
29 Oct 2026Senior Software Engineer, Site ReliabilitySRE, DevOps & infrastructureRemote
29 Oct 2026Postmarket Quality ManagerTest, quality & reliabilityBrisbane, California
15 Oct 2026Automation Service Engineer IIField service & installationBrisbane, California

Reported lobbying spend: $50K in Q3 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
1 Jul 2026NewTodd Strategy Groupfor FreenomeGeneral education about Freenome. Medicare coverage and reimbursement for diagnostics.Health issues, Medicare/MedicaidFiling

The 5 newest of 90 articles that name the company.

Timeline
Kind of data

Timeline

Changes and notable records, by the date each became public

  1. 25 Oct 2026Lobbying change

    registered for federal lobbying for the first time in our data (Todd Strategy Group).

    See the evidence (1 source record)
    Source coverage starts
    3 Jan 2008
    Earlier events of other kinds
    0

    "First" means first in our data: it fires only when the source's history began at least 365 days earlier.

  2. 25 Oct 2026Lobbying record

    FREENOME: new lobbying registration (TODD STRATEGY GROUP) (dated 1 Jul 2026)

  3. 18 Aug 2026Filings record

    Registered new securities for sale (S-1)

  4. 24 Jul 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  5. 24 Jul 2026Filings record

    Director or officer change (dated 23 Jul 2026)

  6. 24 Jul 2026Filings record

    Changed its auditor (dated 23 Jul 2026)

  7. 24 Jul 2026Filings record

    Completed an acquisition or asset sale (dated 23 Jul 2026)

  8. 7 Jun 2024Filings record

    Registered new securities for sale (S-1)

  9. 21 May 2024Filings record

    Registered new securities for sale (S-1)

Not listed: 20 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0002017526
Ticker
FRNM
Domain
freenome.com
Employer name
freenome holdings, Freenome, LLC (1 unverified)
Fein
42-2933677 (1 unverified)
Hq location
CA|BRISBANE|94005 (1 unverified)
Lobbying client
freenome
Name
Freenome, Inc., Perceptive Capital Solutions Corp
  • DOL H-1B labor condition applications and PERM certifications18 data points20 Apr 2026 to 14 Sep 2026
  • Federal lobbying disclosures (LDA)1 record, 3 data points1 Jul 2026 to 30 Sep 2026
  • SEC Form 13F institutional holdings9 data points30 Sep 2026 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)26 records21 May 2024 to 12 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)96 data points21 Mar 2024 to 9 Nov 2026
  • FINRA short interest (twice monthly)20 data points31 Jul 2026 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)176 data points21 Jul 2026 to 20 Nov 2026